Powered by healthtechmovers.com
According to healthtechmovers.com, there are a few trending healthtech stocks that have recently received buy ratings and showing positive investor sentiment, as well as news headlines. With that said, the editors over at healthtechmovers.com, are adding the stocks below to their healthtech stock watchlist. That staff here at wallstreetmovers.com, will continue to monitor these healthtech companies to see if the momentum continues. WallStreetMovers.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE..
Recent ICPT Stock Price: $18.60
Summary: Intercept Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing novel therapeutics to treat chronic liver diseases to market. The company's focus is on treating orphan and more prevalent liver diseases with limited treatment options. The company received FDA approval for Ocaliva an farnesoid X receptor against in combination with ursodeoxycholic acid, for the treatment of primary biliary cholangitis in adults with an inadequate response to UDCA or as monotherapy in adults who are intolerant to UDCA. Ocaliva was approved in the EU for the same indication. The drug was approved in Canada. OCA is also being developed for additional indications like primary sclerosing cholangitis and non-alcoholic steatohepatitis. The FDA accepted its New Drug Application for OCA seeking accelerated approval for the treatment of fibrosis due to NASH. Intercept received a complete response letter from the FDA stating that its NDA for OCA for the treatment of liver fibrosis due to NASH could not be approved.
Ritu Baral analyst at TD Cowen reiterates coverage on Intercept Pharma (ICPT) stock in the energy sector with a Hold rating and has set ICPT's stock price target at $19.
TipRanks.com reports that Intercept Pharma currently has 5 analysts offering 12-month price targets on ICPT and the consensus is a Hold rating with an average stock price target of $19.00. The most recent ICPT stock price we have is $18.60 and we are not making any ICPT forecasts at this time.
In addition, TradingView issued a Buy rating for ICPT over the next month, Barchart.com has a Weak buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on ICPT. wallstreetmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ICPT, please click here >>
Recent ILMN Stock Price: $136.44
Summary: Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, and gene expression profiling of DNA and RNA. Its customers include leading genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories as well as pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Illumina generates revenue from two segments - Product and Service. Product are primarily attributed to the partnerships and collaborations to develop distributable clinical in-vitro diagnostics for Illumina sequencers. Service include genotyping and sequencing services as well as instrument maintenance contracts.
Shubhangi Gupta analyst at HSBC reiterates coverage on Illumina (ILMN) stock in the energy sector with a Buy rating and has set ILMN's stock price target at $170.
TipRanks.com reports that Illumina currently has 5 analysts offering 12-month price targets on ILMN and the consensus is a Hold rating with an average stock price target of $166.00. The most recent ILMN stock price we have is $136.44 and we are not making any ILMN forecasts at this time.
In addition, TradingView issued a Sell rating for ILMN over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ILMN. wallstreetmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on ILMN, please click here >>
Recent FOLD Stock Price: $11.03
Summary: Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.'The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.'The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.'The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Anupam Rama analyst at J.P. Morgan reiterates coverage on Amicus (FOLD) stock in the energy sector with a Buy rating and has set FOLD's stock price target at $19.
TipRanks.com reports that Amicus currently has 5 analysts offering 12-month price targets on FOLD and the consensus is a Strong Buy rating with an average stock price target of $18.80. The most recent FOLD stock price we have is $11.03 and we are not making any FOLD forecasts at this time.
In addition, TradingView issued a Strong Sell rating for FOLD over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on FOLD. wallstreetmovers.com is not recommending this stock, we are just providing you with compiled information.
For the complete breakdown on FOLD, please click here >>
The editors at wallstreetmovers.com use a variety of research tools to generate our watchlists and research reports. One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star RankingTM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
WallStreetMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetMovers.com.
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.